Cargando…

The different benefits and side effects of nivolumab combined with ipilimumab in diverse cancer: A Protocol for Systematic Review

INTRODUCTION: This systematic review protocol aims to provide the methods used to assess the total benefits and side effects in all cancer patients and their respective benefits and side effects in different cancers. METHODS AND ANALYSIS: The following electronic bibliographic databases will be sele...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tong, Hongxuan, Hao, Yu, Wang, Kaili, Xiang, Lekang, Lu, Tao
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Wolters Kluwer Health 2020
Materias:	5700
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7220411/ https://www.ncbi.nlm.nih.gov/pubmed/32176058 http://dx.doi.org/10.1097/MD.0000000000019367

Ejemplares similares

Risks and benefits of reinduction ipilimumab/nivolumab in melanoma patients previously treated with ipilimumab/nivolumab
por: Chapman, Paul B, et al.
Publicado: (2021)

Healthcare cost comparison analysis of nivolumab in combination with ipilimumab versus nivolumab monotherapy and ipilimumab monotherapy in advanced melanoma
por: Potluri, Ravi, et al.
Publicado: (2019)

Nivolumab plus regorafenib in patients with small bowel adenocarcinoma: A case report
por: Zhang, Gairong, et al.
Publicado: (2021)

A case report of immune checkpoint inhibitor nivolumab combined with anti-angiogenesis agent anlotinib for advanced esophageal squamous cell carcinoma
por: Tang, Yong, et al.
Publicado: (2019)

Nivolumab as adjuvant treatment for a spinal melanocytoma: A case report
por: Hean, Virginie, et al.
Publicado: (2021)

Adverse events induced by nivolumab and ipilimumab combination regimens
por: Somekawa, Kohei, et al.
Publicado: (2022)

Combined Nivolumab and Ipilimumab in Octogenarian and Nonagenarian Melanoma Patients
por: Reichert, Constance, et al.
Publicado: (2023)

Case report: pathological complete response in an IIIB non-small cell lung cancer patient after preoperative neoadjuvant nivolumab therapy combined with chemotherapy
por: Li, Luzhen, et al.
Publicado: (2022)

Estimating Cardiac Substructures Exposure From Diverse Radiotherapy Techniques in Treating Left-Sided Breast Cancer
por: Zhang, Li, et al.
Publicado: (2015)

The risks of hematological toxicities of nivolumab in cancer patients: A PRISMA-compliant meta-analysis
por: Shi, Zuolin, et al.
Publicado: (2022)

Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma
por: Wolchok, Jedd D., et al.
Publicado: (2022)

Retrospective Side Effect Profiling of the Metastatic Melanoma Combination Therapy Ipilimumab-Nivolumab Using Adverse Event Data
por: Soldatos, Theodoros G., et al.
Publicado: (2018)

Nivolumab-induced myasthenia gravis in a patient with squamous cell lung carcinoma: Case report
por: Chen, Yu-Hsiu, et al.
Publicado: (2017)

Skeletal muscle mass predicts the outcome of nivolumab treatment for non-small cell lung cancer
por: Tsukagoshi, Mariko, et al.
Publicado: (2020)

Immune-related sarcoidosis observed in combination ipilimumab and nivolumab therapy
por: Suozzi, Kathleen C., et al.
Publicado: (2016)

Population Pharmacokinetics of Nivolumab in Combination With Ipilimumab in Patients With Advanced Malignancies
por: Zhang, Jason, et al.
Publicado: (2019)

Comparative efficacy of Chinese herbal injections combined with GP regimen chemotherapy for patients with advanced NSCLC: A protocol for systematic review and network meta-analysis
por: Li, Juan, et al.
Publicado: (2020)

Not only for melanoma. Subcutaneous pseudoprogression in lung squamous-cell carcinoma treated with nivolumab: A case report
por: Sarfaty, Michal, et al.
Publicado: (2017)

A case report on severe nivolumab-induced adverse events similar to primary sclerosing cholangitis refractory to immunosuppressive therapy
por: Hirasawa, Yuya, et al.
Publicado: (2021)

Effectiveness of different acupuncture therapies for chronic cancer pain: A protocol for systematic review and Bayesian network meta-analysis
por: Wan, Qingyun, et al.
Publicado: (2022)

Lung brain metastasis pseudoprogression after nivolumab and ipilimumab combination treatment
por: Melian, Marcos, et al.
Publicado: (2018)

Population Pharmacokinetics of Ipilimumab in Combination With Nivolumab in Patients With Advanced Solid Tumors
por: Sanghavi, Kinjal, et al.
Publicado: (2019)

Nivolumab and Ipilimumab Combination Immunotherapy for Patients with Metastatic Collecting Duct Carcinoma
por: Danno, Tetsuya, et al.
Publicado: (2021)

The best dosage of nivolumab plus ipilimumab combination for melanoma brain metastases
por: Fukumoto, Takeshi, et al.
Publicado: (2022)

A Randomized Phase 2 Trial of Nivolumab Versus Nivolumab-Ipilimumab Combination in EGFR-Mutant NSCLC
por: Lai, Gillianne G.Y., et al.
Publicado: (2022)

COX-2 Promotes Migration and Invasion by the Side Population of Cancer Stem Cell-Like Hepatocellular Carcinoma Cells
por: Guo, Zhe, et al.
Publicado: (2015)

Nivolumab plus ipilimumab in the treatment of advanced melanoma
por: Tsai, Katy K., et al.
Publicado: (2015)

Severe Gastritis after Administration of Nivolumab and Ipilimumab
por: Nishimura, Yoshito, et al.
Publicado: (2018)

Ipilimumab/nivolumab: Diffuse pneumonitis: case report
Publicado: (2020)

Ipilimumab and nivolumab for recurrent neuroendocrine cervical carcinoma
por: Towner, Mary, et al.
Publicado: (2022)

Prognostic role of urokinase plasminogen activator in hepatocellular carcinoma: A protocol for systematic review and meta analysis
por: Tao, Pengxian, et al.
Publicado: (2020)

Efficacy of short-term nivolumab treatment in a Chinese patient with relapsed advanced-stage lung squamous cell carcinoma: A case report
por: Pi, Guoliang, et al.
Publicado: (2016)

Effects of S-1 combined with radiotherapy in the treatment of advanced esophageal cancer: A systematic review and meta-analysis protocol
por: Wang, Wei, et al.
Publicado: (2018)

Clinical benefits of FOLFOXIRI combined with bevacizumab for advanced-stage primary signet ring cell carcinoma of the appendix: A case report
por: Huang, Nana, et al.
Publicado: (2023)

The association between body mass index and the risk of different urinary cancers: Protocol for an overview of systematic reviews
por: Zhao, Wenli, et al.
Publicado: (2020)

Combination immune checkpoint inhibitor therapy nivolumab and ipilimumab associated with multiple endocrinopathies
por: Gunawan, Florence, et al.
Publicado: (2018)

Combination of Ipilimumab and Nivolumab in Cancers: From Clinical Practice to Ongoing Clinical Trials
por: Kooshkaki, Omid, et al.
Publicado: (2020)

Early Response Assessment in Advanced Stage Melanoma Treated with Combination Ipilimumab/Nivolumab
por: Ma, Vincent T., et al.
Publicado: (2022)

Efficacy and toxicity of Ipilimumab-Nivolumab combination therapy in elderly metastatic melanoma patients
por: Stoff, Ronen, et al.
Publicado: (2022)

Diagnostic value of routine ultrasonography combined with ultrasound elastography for papillary thyroid microcarcinoma: A protocol for systematic review and meta-analysis
por: Du, Yanfei, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_m4d7gdtfk7va49c2ioeqcm8brn